This week in drug discovery (22-26 May)

News round-up for 22-26 May by DDW Digital Content Editor Diana Spencer.

The theme of our news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and investing in new facilities, as well as government support coming through to boost research in areas of urgent need.

The top stories:

Biopharma investment drops by nearly 50% in 2022

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report.

$7.5M investment to target cancer and neurological diseases

PharmEnable has closed a pre-series A investment round of $7.5 million to develop the next generation of small molecule drugs against disease areas of high clinical need.

New London facility exceeds global plasmid DNA demand

Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK.

UK government invests £39 million in AMR research

The UK government will invest up to £39 ($48) million in antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF).

Danish immunotherapy start-up raises €6M seed funding

Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free